AR119376A1 - Compuestos heterocíclicos - Google Patents

Compuestos heterocíclicos

Info

Publication number
AR119376A1
AR119376A1 ARP200101928A ARP200101928A AR119376A1 AR 119376 A1 AR119376 A1 AR 119376A1 AR P200101928 A ARP200101928 A AR P200101928A AR P200101928 A ARP200101928 A AR P200101928A AR 119376 A1 AR119376 A1 AR 119376A1
Authority
AR
Argentina
Prior art keywords
alkyl
alkoxy
halo
aryl
halogen
Prior art date
Application number
ARP200101928A
Other languages
English (en)
Inventor
Hans Richter
Fionn Ohara
Uwe Grether
Benoit Hornsperger
Bernd Kuhn
Maurice Biedermann
Miroslav Kosar
Flore Reggiani
Carsten Kroll
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR119376A1 publication Critical patent/AR119376A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Abstract

Reivindicación 1: Compuesto de fórmula (1) o una sal farmacéuticamente aceptable del mismo, en la que: X es -CH₂CR³R⁴- o -CH=CR³ -, Y es -O-, -S-, -SO-, o -SO₂-, R¹ es arilo C₆₋₁₄ o heteroarilo de 5 a 14 elementos, en el que dicho arilo C₆₋₁₄ o heteroarilo de 5 a 14 elementos se sustituye opcionalmente con 1 a 5 sustituyentes seleccionados independientemente de alquilo C₁₋₆, alcoxi C₁₋₆, halo-alquilo C₁₋₆, halo-alcoxi C₁₋₆, halógeno, ciano, hidroxi y un grupo de fórmula (2), R² es hidrógeno o alquilo C₁₋₆, R³ es un grupo de fórmula (3), R⁴ es hidrógeno, halógeno o hidroxi, R⁵ es hidrógeno, halógeno, hidroxi, amino, halo-alquilo C₁₋₆, alcoxi C₁₋₆, alquilo C₁₋₆, halo-alcoxi C₁₋₆, ciano o oxo, R⁶ es hidrógeno, halógeno, arilo C₆₋₁₄, heteroarilo de 5 a 14 elementos, haloalcoxi C₁₋₆, halo-alquilo C₁₋₆, oxo, alquilo C₁₋₆, alcoxi C₁₋₆, alquenilo C₂₋₆, alquinilo C₂₋₆, cicloalquilo C₃₋₁₄ o ciano, en el que dicho heteroarilo de 5 a 14 elementos o arilo C₆₋₁₄ se sustituye opcionalmente con 1 a 2 sustituyentes seleccionados de halógeno, ciano, amino, hidroxi, alquilo C₁₋₆ y alcoxi C₁₋₆, A y B son, cada uno independientemente, heteroarilo de 5 a 14 elementos, arilo C₆₋₁₄, heterociclilo de 3 a 14 elementos o cicloalquilo C₃₋₁₄, y n y p son, cada uno independientemente, 1, 2, 3, 4 ó 5.
ARP200101928A 2019-07-09 2020-07-08 Compuestos heterocíclicos AR119376A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP19185088 2019-07-09

Publications (1)

Publication Number Publication Date
AR119376A1 true AR119376A1 (es) 2021-12-15

Family

ID=67220669

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP200101928A AR119376A1 (es) 2019-07-09 2020-07-08 Compuestos heterocíclicos

Country Status (18)

Country Link
US (1) US20220242876A1 (es)
EP (1) EP3997096A1 (es)
JP (1) JP2022539604A (es)
KR (1) KR20220034104A (es)
CN (1) CN114096545A (es)
AR (1) AR119376A1 (es)
AU (1) AU2020311584A1 (es)
BR (1) BR112021026899A2 (es)
CA (1) CA3145338A1 (es)
CL (1) CL2022000019A1 (es)
CO (1) CO2022000186A2 (es)
CR (1) CR20220004A (es)
IL (1) IL288987A (es)
MX (1) MX2022000243A (es)
PE (1) PE20220515A1 (es)
TW (1) TW202116781A (es)
WO (1) WO2021005034A1 (es)
ZA (1) ZA202110352B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019134985A1 (en) 2018-01-08 2019-07-11 F. Hoffmann-La Roche Ag Octahydropyrido[1,2-alpha]pyrazines as magl inhibitors
EP3837263A1 (en) 2018-08-13 2021-06-23 F. Hoffmann-La Roche AG New heterocyclic compounds as monoacylglycerol lipase inhibitors
EP4028403B1 (en) 2019-09-12 2023-11-22 F. Hoffmann-La Roche AG 4,4a,5,7,8,8a-hexapyrido[4,3-b][1,4]oxazin-3-one compounds as magl inhibitors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2014110401A (ru) * 2011-08-19 2015-09-27 Мерк Шарп И Доум Корп. Ингибиторы внешнего медуллярного калиевого канала почек
EP2934533B1 (en) * 2012-12-19 2017-11-15 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
US10323038B2 (en) * 2015-11-20 2019-06-18 Abide Therapeutics, Inc. Pyrazole compounds and methods of making and using same
BR112019014099A2 (pt) * 2017-01-23 2020-02-11 Pfizer Inc. Compostos espiro-heterocíclico como inibidores de magl
JOP20190267A1 (ar) * 2017-05-23 2019-11-18 Lundbeck La Jolla Research Center Inc مثبطات بيرازول magl

Also Published As

Publication number Publication date
CR20220004A (es) 2022-01-31
BR112021026899A2 (pt) 2022-05-10
CN114096545A (zh) 2022-02-25
JP2022539604A (ja) 2022-09-12
AU2020311584A1 (en) 2022-01-20
MX2022000243A (es) 2022-02-03
EP3997096A1 (en) 2022-05-18
KR20220034104A (ko) 2022-03-17
PE20220515A1 (es) 2022-04-07
IL288987A (en) 2022-02-01
TW202116781A (zh) 2021-05-01
CO2022000186A2 (es) 2022-01-17
US20220242876A1 (en) 2022-08-04
WO2021005034A1 (en) 2021-01-14
ZA202110352B (en) 2022-08-31
CL2022000019A1 (es) 2022-10-21
CA3145338A1 (en) 2021-01-14

Similar Documents

Publication Publication Date Title
AR110405A1 (es) Compuestos
AR119376A1 (es) Compuestos heterocíclicos
AR104884A1 (es) Compuestos de 4-hidroxi-3-(heteroaril)piridin-2-ona como agonistas de apj
AR121044A1 (es) Inhibidores de egfr
AR100645A1 (es) Derivados de pirazolo-pirimidina
AR109179A1 (es) Inhibidores de diacilglicerol aciltransferasa 2
AR117139A1 (es) Derivados de piridooxazinona como inhibidores de monoacilglicerol ligasa (magl)
AR107061A1 (es) Heteroarilhidroxipirimidinonas como agonistas del receptor de apj
AR095311A1 (es) 3-pirimidin-4-il-oxazolidin-2-onas como inhibidores de idh mutante
AR119943A1 (es) Compuestos heterocíclicos
AR113929A1 (es) Compuestos heterocíclicos
AR099498A1 (es) Compuestos de triazina y su uso farmacéutico
AR088829A1 (es) DERIVADOS DE CICLOHEXILAMINA QUE TIENEN ACTIVIDAD COMO AGONISTAS ADRENERGICOS b2 Y COMO ANTAGONISTAS MUSCARINICOS M3
AR099789A1 (es) Derivados de 8-(piperazin-1-il)-1,2,3,4-tetrahidro-isoquinolina
AR109711A1 (es) Inhibidores de fosfatidilinositol 3-quinasa
AR090557A1 (es) DERIVADOS IMIDAZOLICOS AGONISTAS ADRENERGICOS a2
AR091208A1 (es) Derivados de piperidina
AR113842A1 (es) Derivados de tiazol microbiocidas
AR115085A1 (es) DERIVADOS DE 3-AMINO-2,4,6-TRIAZINA COMO INHIBIDORES DE LA TIROSINA CINASA DE BRUTON (Btk)
AR119790A1 (es) Compuestos de isoxazolina y su uso como agentes para el control de plagas
AR111252A1 (es) Compuestos de isoxazol carboxamida y usos de los mismos
AR101798A1 (es) Quinolinas herbicidas
AR122517A1 (es) Isoxazolidinas como inhibidores de ripk1 y usos de las mismas
AR122726A1 (es) Compuestos de unión de cereblon, composiciones de los mismos, y métodos de tratamiento con los mismos
AR112463A1 (es) Derivados de propanamina para tratar el dolor y estados relacionados con dolor